Recombinant Relaxin Protects Liver Transplants from Ischemia Damage via Hepatocyte Glucocorticoid Receptor: From Bench ‐to‐Bedside

Conclusion: This translational study underscores the role of rhRLX – GR signaling as a novel regulator of hepatocellular protection against IR‐stress in OLT. In the context of a recent phase III clinical trial demonstrating positive outcomes of rhRLX in patients with acute heart failure, studies on rhRLX for the management of IRI in liver transplant recipients are warranted. This article is protected by copyright. All rights reserved.

Source: Hepatology - January 20, 2018 Category: Internal Medicine Authors: Shoichi Kageyama, Kojiro Nakamura, Takehiro Fujii, Bibo Ke, Rebecca A Sosa, Elaine F. Reed, Nakul Datta, Ali Zarrinpar, Ronald W. Busuttil, Jerzy W. Kupiec ‐Weglinski Tags: Liver Injury and Regeneration Source Type: research